Novartis Says Chair Contradicted Admissions In FCA Deal

By Adam Lidgett · March 26, 2021, 8:08 PM EDT

Novartis said its chairman incorrectly contradicted the company's admissions that it made as part of a $678 million deal with the federal government to settle claims it flouted the False Claims...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

United States Of America v. Novartis Pharmaceuticals Corporation

Case Number

1:11-cv-00071

Court

New York Southern

Nature of Suit

Other Statutory Actions

Date Filed

January 05, 2011